Cystic fibrosis care has seen such rapid advances that the average CF patient has experienced a dramatic evolution in treatment strategies in their lifetime. Here are some of the biggest milestones that shaped modern-day CF treatments.
Polyphor launches the development of an inhaled antibiotic murepavadin
Polyphor Ltd has announced the development of an inhaled dosage form of its breakthrough antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections
IUPUI microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs
Individuals with cystic fibrosis, or CF, have a high risk of chronic pneumonia because the thick, sticky mucus that builds up in Continue reading Microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs
Novoclem Therapeutics, a biotech company focused on advancing nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with Continue reading New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’
Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc
Savara, Inc.(NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development Continue reading Phase III study starts AVAIL study
Canadian scientists have discovered a possible way to break through the defences of some antibiotic-resistant respiratory infections.
It’s hoped that the findings could someday benefit people with cystic fibrosis and other chronic lung diseases who are at greater risk of infections. Continue reading Scientists find new way to attack antibiotic-resistant lung infections
New Drug Application Submitted for Linhaliq as Treatment of Pseudomonas Aeruginosa Infection in NCFBE Patients
The pharmaceutical company Aradigm has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq Continue reading New Drug Application Submitted for Treatment of P. aeruginosa
CARB-X has awarded $8.9M (€7.6M) to Antabio for the development of a new antibiotic against resistant Pseudomonas infections in cystic fibrosis patients.
Antabio is a French company developing new antibiotics to fight the rapidly Continue reading French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic
An investigation led by the University of Pittsburgh School of Medicine has found a link between a new class of bacterial enzymes and the chronic lung inflammation that plagues patients with cystic fibrosis, a terminal lung Continue reading Pitt study links cystic fibrosis lung inflammation to opportunistic bacteria